Katre N - Search Results

1

Analysis of the Thickness of Ligamentum Flavum and Its Relationship With Degenerative Disc Changes at L3-4, L4-5, and L5-S1 Levels in Patients Undergoing Magnetic Resonance Imaging (MRI) of the Lumbosacral Spine.

Kumar G, Sakalecha AK, Krishnan J, Kale R M, Katre N. Kumar G, et al. Among authors: katre n. Cureus. 2024 Nov 22;16(11):e74233. doi: 10.7759/cureus.74233. eCollection 2024 Nov. Cureus. 2024. PMID: 39712721 Free PMC article.

2

The sustained granulopoietic effect of progenipoietin encapsulated in multivesicular liposomes.

Ramprasad MP, Amini A, Kararli T, Katre NV. Ramprasad MP, et al. Among authors: katre nv. Int J Pharm. 2003 Aug 11;261(1-2):93-103. doi: 10.1016/s0378-5173(03)00291-6. Int J Pharm. 2003. PMID: 12878398

3

Modulation of the sustained delivery of myelopoietin (Leridistim) encapsulated in multivesicular liposomes (DepoFoam).

Langston MV, Ramprasad MP, Kararli TT, Galluppi GR, Katre NV. Langston MV, et al. Among authors: katre nv. J Control Release. 2003 Apr 14;89(1):87-99. doi: 10.1016/s0168-3659(03)00073-7. J Control Release. 2003. PMID: 12695065

4

Sustained-delivery of an apolipoprotein E-peptidomimetic using multivesicular liposomes lowers serum cholesterol levels.

Ramprasad MP, Anantharamaiah GM, Garber DW, Katre NV. Ramprasad MP, et al. Among authors: katre nv. J Control Release. 2002 Feb 19;79(1-3):207-18. doi: 10.1016/s0168-3659(01)00552-1. J Control Release. 2002. PMID: 11853932

5

DepoFoam technology: a vehicle for controlled delivery of protein and peptide drugs.

Ye Q, Asherman J, Stevenson M, Brownson E, Katre NV. Ye Q, et al. Among authors: katre nv. J Control Release. 2000 Feb 14;64(1-3):155-66. doi: 10.1016/s0168-3659(99)00146-7. J Control Release. 2000. PMID: 10640654

6

Multivesicular liposome (DepoFoam) technology for the sustained delivery of insulin-like growth factor-I (IGF-I).

Katre NV, Asherman J, Schaefer H, Hora M. Katre NV, et al. J Pharm Sci. 1998 Nov;87(11):1341-6. doi: 10.1021/js980080t. J Pharm Sci. 1998. PMID: 9811487

7

Development of a lyophilized formulation of interleukin-2.

Hora MS, Rana RK, Wilcox CL, Katre NV, Hirtzer P, Wolfe SN, Thomson JW. Hora MS, et al. Among authors: katre nv. Dev Biol Stand. 1992;74:295-303; discussion 303-6. Dev Biol Stand. 1992. PMID: 1592178

8

Site-directed pegylation of recombinant interleukin-2 at its glycosylation site.

Goodson RJ, Katre NV. Goodson RJ, et al. Among authors: katre nv. Biotechnology (N Y). 1990 Apr;8(4):343-6. doi: 10.1038/nbt0490-343. Biotechnology (N Y). 1990. PMID: 1366535

9

Immunogenicity of recombinant IL-2 modified by covalent attachment of polyethylene glycol.

Katre NV. Katre NV. J Immunol. 1990 Jan 1;144(1):209-13. J Immunol. 1990. PMID: 2295792

10

Schedule dependency of the antitumor activity and toxicity of polyethylene glycol-modified interleukin 2 in murine tumor models.

Zimmerman RJ, Aukerman SL, Katre NV, Winkelhake JL, Young JD. Zimmerman RJ, et al. Among authors: katre nv. Cancer Res. 1989 Dec 1;49(23):6521-8. Cancer Res. 1989. PMID: 2819708

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

19 results

Search Page

Filters